Ramipril and Lung hyperinflation - a phase IV clinical study of FDA data

Summary:

Lung hyperinflation is reported as a side effect among people who take Ramipril (ramipril), especially for people who are female, 60+ old, also take Uniphyl, and have Chronic obstructive pulmonary disease.

The phase IV clinical study analyzes which people have Lung hyperinflation when taking Ramipril. It is created by eHealthMe based on reports of 144,209 people who have side effects when taking Ramipril from the FDA, and is updated regularly.

What is Ramipril?

Ramipril has active ingredients of ramipril. It is often used in high blood pressure. eHealthMe is studying from 147,398 Ramipril users. Check the latest studies of Ramipril.

What is Lung hyperinflation?

Lung hyperinflation (inspiration of more than normal) is found to be associated with 301 drugs and 273 conditions by eHealthMe. Check the latest studies of Lung hyperinflation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

144,209 people reported to have side effects when taking Ramipril.
Among them, 18 people (0.01%) have Lung hyperinflation.

Could Ramipril cause Lung hyperinflation?

Among these 18 people:

What is the gender of people who have Lung hyperinflation when taking Ramipril? *

female: 86.67 %
male: 13.33 %

What is the age of people who have Lung hyperinflation when taking Ramipril? *

What are other drugs people take besides Ramipril? *

What are other side effects people have besides Lung hyperinflation? *

Asthma: 14 people, 77.78%
Obstructive Airways Disorder (a progressive disease that makes it hard to breathe): 12 people, 66.67%
Dyspnea (difficult or laboured breathing): 11 people, 61.11%
Fall: 10 people, 55.56%
Weight Decreased: 9 people, 50.00%
Back Pain: 9 people, 50.00%
Pneumonia: 9 people, 50.00%
Nerve Compression: 8 people, 44.44%
Forced Expiratory Volume Decreased (decreased lung expired air volume): 8 people, 44.44%
Seasonal Allergy (allergic condition due to certain season): 8 people, 44.44%

What are the existing conditions these people have? *

Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 9 people, 50.00%
Asthma: 8 people, 44.44%
Myasthenia Gravis (a chronic condition that causes muscles to tire and weaken easily): 1 person, 5.56%
Hiv Infection: 1 person, 5.56%
Heart Disease: 1 person, 5.56%
Adverse Drug Reaction: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Ramipril and have Lung hyperinflation?

- Check whether Lung hyperinflation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ramipril:

Ramipril (147,398 reports)

Browse all side effects of Ramipril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Lung hyperinflation:

Lung hyperinflation (301 drugs)

Browse all the conditions that are associated with Lung hyperinflation:

Lung hyperinflation (273 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ramipril (the active ingredients of Ramipril) and Ramipril (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.